RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase I, multi center study to evaluate the safety and efficacy and determine the
maximum tolerated dose (MTD) of RP72 as monotherapy and RP72 in combination with Gemcitabine
in patients with pancreatic cancer.
The study has two arms:
Arm A: RP72 monotherapy
Arm B: RP72 in combination with Gemcitabine
Both treatment arms will follow a standard 3+3 design. Up to 48 adult patients with
pancreatic cancer will be enrolled in this study.
Phase:
Phase 1
Details
Lead Sponsor:
Rise Biopharmaceuticals, Inc.
Collaborators:
Amarex Clinical Research T-TOP Clinical Research Co., Ltd.